Incyte | INCY - Cost Of Sales

Stock Price
108.39
Daily Change
5.63 5.48%
Monthly
-1.97%
Yearly
46.22%
Q1 Forecast
96.99

Incyte reported $99M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 21.65M 913K Sep/2025
Agios Pharmaceuticals USD 1.68M 22K Sep/2025
Alnylam Pharmaceuticals USD 200.15M 57.2M Sep/2025
Amgen USD 1.79B 128M Dec/2025
Biogen USD 810.1M 205.1M Sep/2025
BioMarin Pharmaceutical USD 144.93M 10M Sep/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Exelixis USD 18.57M 896K Sep/2025
Gilead Sciences USD 1.57B 68M Sep/2025
Incyte USD 99M 20.23M Sep/2025
Ionis Pharmaceuticals USD 2.34M 1.81M Sep/2025
MacroGenics USD 44.3M 5.4M Sep/2025
Merck USD 3.32B 531M Dec/2025
Moderna USD 207M 88M Sep/2025
Neurocrine Biosciences USD 264M 252.7M Sep/2025
Novartis USD 3.54B 217M Sep/2025
Novartis USD 3.54B 216M Sep/2025
Pfizer USD 6.29B 2.12B Dec/2025
PTC Therapeutics USD 23.32M 7.83M Sep/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Sarepta Therapeutics USD 151.45M 1.77M Sep/2025
Ultragenyx Pharmaceutical USD 27.99M 4.99M Sep/2025
Vertex Pharmaceuticals USD 414.8M 7.3M Sep/2025